Module

Current Treatment Options for Chronic Myelogenous Leukemia

Source: Treatment of Chronic Myeloid Leukemia

Current Treatment Options for Chronic Myelogenous Leukemia

Faculty:
Hagop M. Kantarjian, MD Jorge E. Cortes, MD Elias Jabbour, MD

CME CREDIT INFORMATION

Release Date: 12/12/06

Expiration Date: 12/11/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe optimal initial treatment strategies for chronic myelogenous leukemia (CML)
Discuss laboratory tests used to monitor responses in patients with CML being treated with imatinib therapy
Discuss treatment options for patients with CML who are resistant to or intolerant of imatinib therapy

Topics covered include:

Introduction
Imatinib Update
Imatinib Dose Schedules
Monitoring of Imatinib Therapy and Minimal Residual Disease
Imatinib Resistance
New Bcr-Abl Inhibitors
Dasatinib Clinical Trials
Nilotinib
Nilotinib Clinical Trials
Other Tyrosine Kinase Inhibitors
Other Therapeutic Approaches
Conclusion

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.